We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-1.23%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$145M
Cap. Flow
+$20.1M
Cap. Flow %
0.74%
Top 10 Hldgs %
78.13%
Holding
30
New
1
Increased
8
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
MYOV
Myovant Sciences Ltd.
MYOV
+$37M
2
MGNX icon
MacroGenics
MGNX
+$11.7M
3
JUNO
Juno Therapeutics, Inc.
JUNO
+$11.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$6.12M

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$49.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$9.89M
3
PTCT icon
PTC Therapeutics
PTCT
+$5.25M

Sector Composition

Rank Sector Weight
1 Healthcare 91.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$400M 14.83%
3,459,298
– –
INCY icon
2
Incyte
INCY
$24.4B
$389M 14.41%
3,879,822
– –
IONS icon
3
Ionis Pharmaceuticals
IONS
$9.4B
$331M 12.25%
6,913,172
-250,000
-3% -$9.89M
GILD icon
4
Gilead Sciences
GILD
$165B
$199M 7.36%
2,774,596
– –
RDUS
5
DELISTED
Radius Health, Inc.
RDUS
$166M 6.14%
4,360,399
– –
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$150M 5.57%
1,229,428
+50,000
+4% +$6.12M
TSRO
7
DELISTED
TESARO, Inc.
TSRO
$131M 4.85%
974,582
– –
NBIX icon
8
Neurocrine Biosciences
NBIX
$16.6B
$122M 4.52%
3,151,552
+30,000
+1% +$1.36M
AGIO icon
9
Agios Pharmaceuticals
AGIO
$1.93B
$117M 4.34%
2,809,528
+160,000
+6% +$8.4M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$126B
$104M 3.86%
1,415,445
– –
REGN icon
11
Regeneron Pharmaceuticals
REGN
$80.8B
$89.9M 3.33%
245,000
– –
HALO icon
12
Halozyme
HALO
$12.2B
$75.1M 2.78%
7,599,832
+220,000
+3% +$2.41M
SAGE
13
DELISTED
Sage Therapeutics
SAGE
$52.2M 1.93%
1,022,439
– –
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$29.3B
$44.6M 1.65%
1,191,338
– –
MYOV
15
DELISTED
Myovant Sciences Ltd.
MYOV
$39.7M 1.47%
+3,192,835
New +$37M
MGNX icon
16
MacroGenics
MGNX
$257M
$39.2M 1.45%
1,920,000
+465,000
+32% +$11.7M
KITE
17
DELISTED
Kite Pharma, Inc.
KITE
$35.9M 1.33%
800,000
– –
JUNO
18
DELISTED
Juno Therapeutics, Inc.
JUNO
$35.3M 1.31%
1,870,000
+465,000
+33% +$11.4M
ALDR
19
DELISTED
Alder Biopharmaceuticals
ALDR
$35.1M 1.3%
1,685,150
– –
ICPT
20
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$27.8M 1.03%
255,719
– –
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$23.8M 0.88%
1,575,000
+225,000
+17% +$3.18M
PRTA icon
22
Prothena Corp
PRTA
$450M
$17.2M 0.64%
350,000
– –
AVXS
23
DELISTED
AveXis, Inc. Common Stock
AVXS
$16.8M 0.62%
352,800
– –
ESPR
24
DELISTED
Esperion Therapeutics
ESPR
$16.4M 0.61%
1,308,542
– –
CDTX
25
DELISTED
Cidara Therapeutics
CDTX
$10.9M 0.4%
52,191
+14,850
+40% +$3.09M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2016 Portfolio in Review

As of Q4 2016, BB Biotech held 30 positions worth $2.7B, down 5.1% from $2.84B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

BB Biotech's Q4 2016 filing shows 1 new, 8 increased, 2 reduced and 1 closed positions. Its largest new stake was Myovant Sciences Ltd.: 3,192,835 shares worth $39.7M. The largest sale was Cempra, Inc., an estimated $49.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.

  • BB Biotech's largest Q4 2016 buy was Myovant Sciences Ltd.: 3,192,835 shares worth $39.7M.
  • BB Biotech added most to MacroGenics in Q4 2016, an estimated $11.7M increase.
  • BB Biotech's biggest Q4 2016 reduction was Ionis Pharmaceuticals, cutting an estimated $9.89M.
  • BB Biotech fully exited Cempra, Inc. in Q4 2016, selling an estimated $49.4M.
  • BB Biotech's ten largest holdings make up 78% of its $2.7B portfolio in Q4 2016.
  • BB Biotech opened 1 new position and closed 1 in Q4 2016.
  • BB Biotech's portfolio value fell 5.1% quarter-over-quarter to $2.7B.

Based on BB Biotech's 13F filing for Q4 2016, filed 14 Feb 2017.